Mohammed Haneefa Nizamudeen
After the
failure of Intercept Prescription drugs’ (ICPT) Ocaliva (obeticolic acid) for nonalcoholic steatohepatitis (NASH) in June, the corporate was destined to be acquired.
GlobalData argues that with out every other late-stage candidates in its pipeline and with its share worth dropping precipitously, an acquisition was the most effective — and maybe solely — possibility for Intercept (NASDAQ:ICPT).
Whereas Ocaliva is authorised for main biliary cholangitis, that market is tiny in comparison with the one for NASH. GlobalData tasks 600K complete instances of PBC in main markets in 2027.
The info and evaluation agency mentioned that the market dimension for NASH is projected to surpass $25B by 2029. “Because of this, Intercept’s future was predicated on its potential in NASH,” mentioned GlobalData Pharma Analyst Jay Patel.
He added that Intercept’s (ICPT) incapability to change into a frontrunner in NASH prevented it from turning into a bigger pharma firm. The Ocaliva failure in NASH led to a plunge within the firm’s inventory worth, making it fund different applications.
Patel famous that Intercept’s (ICPT) pipeline, comparable to INT-787, a Part IIa asset for for extreme alcohol-associated hepatitis, enhances Alfasigma’s deal with metabolic and gastroenterological illnesses.
The Italian pharma markets Xifaxan (rifaximin) for decreasing the chance of overt hepatic encephalopathy and irritable bowel syndrome with diarrhea, in addition to Carnitene (L-carnitine) for carnitine deficiency in sufferers with finish stage renal illness.
